← ANALYST RATINGS · TIPRANKS
AN2 Therapeutics, Inc. (ANTX): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $9.00, the highest $9.00, the lowest $9.00. The average is +166.3% from the last price of $3.38.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $3.50−22.2% | Hold | +3.6% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Sell | +3.6% | Downgrade | 14.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $3.50−22.2% | Hold | +3.6% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $3.50−22.2% | Sell | +3.6% | Downgrade | 14.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $3.50−22.2% | Hold | +3.6% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $3.50−22.2% | Sell | +3.6% | Downgrade | 14.10.26on TipRanks 03:05 | — | |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $9.00 | Buy | +166.3% | Initiated | 19.07.26on TipRanks Jul 20 05:15 | +2.7%next day +3.3% · 5 days +3.1% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $9.00 | Buy | +166.3% | Upgrade | 15.05.26on TipRanks May 14 06:15 | +6.9%next day +3.6% · 5 days +6.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering AN2 Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.00 at a price of $5.32 (+69.2%); now: $9.00 at $3.38 (+166.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.20 to $-0.20). Last quarter: $-0.18.
Best top-analyst consensus in the sector · Healthcare
About AN2 Therapeutics, Inc.
- CEO: Eric E. Easom
- Employees: 21
- 1800 El Camino Real, Menlo Park, CA, 94025, US
- www.an2therapeutics.com
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 469 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗